Randomized phase II trial of irinotecan and bevacizumab as neo-adjuvant and adjuvant to temozolomide-based chemoradiation compared with temozolomide-chemoradiation for unresectable glioblastoma: final results of the TEMAVIR study from ANOCEF †
Titel:
Randomized phase II trial of irinotecan and bevacizumab as neo-adjuvant and adjuvant to temozolomide-based chemoradiation compared with temozolomide-chemoradiation for unresectable glioblastoma: final results of the TEMAVIR study from ANOCEF †
Auteur:
Chauffert, B. Feuvret, L. Bonnetain, F. Taillandier, L. Frappaz, D. Taillia, H. Schott, R. Honnorat, J. Fabbro, M. Tennevet, I. Ghiringhelli, F. Guillamo, J.S. Durando, X. Castera, D. Frenay, M. Campello, C. Dalban, C. Skrzypski, J. Chinot, O.